Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Dow
Deloitte
Accenture
Chinese Patent Office
Johnson and Johnson
Chubb
Cipla
Daiichi Sankyo
QuintilesIMS

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
Abstract:Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.
Inventor(s): Kennedy; James C. (Kingston, CA), Pottier; Roy H. (Kingston, CA), Reid; Robert L. (Kingston, CA), Sac-Morales; Arnold (Kingston, CA), Tomalty; Lewis L. (Inverary, CA)
Assignee: Queen's University at Kingston (Kingston, CA)
Filing Date:Jun 05, 1995
Application Number:08/465,242
Claims:1. A method for treating acne, comprising administering a therapeutically effective amount of a precursor of protoporphyrin IX to a patient in need of such treatment, and thereafter exposing the patient to light capable of photoactiviating protoporphyrin IX.

2. A method according to claim 1, wherein said acne is associated with the presence of a Propinobacterium.

3. A method according to claim 1, wherein said precursor is 5-aminolevulinic acid.

4. A method for treating a patient suffering from a disorder associated with a Propinobacterium, comprising administering a therapeutically effective amount of a precursor of protoporphyrin IX to said patient, and thereafter exposing the patient to light capable of photoactiviating protoporphyrin IX.

5. A method according to claim 4, wherein said precursor is 5-aminolevulinic acid.

6. A method for treating malaria, comprising administering a therapeutically effective amount of a precursor of protoporphyrin IX to a patient in need of such treatment, and thereafter exposing the patient to light capable of photoactiviating protoporphyrin IX.

7. A method according to claim 6, wherein said malaria is associated with the presence of a malarial parasite.

8. A method according to claim 7, wherein said parasite is selected from the group consisting of Plasmodium falciparum, Plasmodium ovale, Plasmodium malaria, and Plasmodium vivax.

9. A method for treating a patient suffering from a disorder associated with the presence of a parasite selected from the group consisting of Plasmodium falciparum, Plasmodium ovale, Plasmodium malaria, and Plasmodium vivax, comprising administering a therapeutically effective amount of a precursor of protoporphyrin IX to said patient, and thereafter exposing the patient to light capable of photoactiviating protoporphyrin IX.

10. A method according to claim 6, wherein said precursor is 5-aminolevulinic acid.

11. A method for treating a skin lesion that is associated with the presence of a bacterium, comprising administering a therapeutically effective amount of a precursor of protoporphyrin IX to a patient in need of such treatment, and thereafter exposing the patient to light capable of photoactiviating protoporphyrin IX.

12. A method according to claim 11, wherein said precursor is 5-aminolevulinic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Covington
Colorcon
Argus Health
Cipla
Dow
Farmers Insurance
Citi
US Department of Justice
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot